JP2017532374A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532374A5 JP2017532374A5 JP2017535609A JP2017535609A JP2017532374A5 JP 2017532374 A5 JP2017532374 A5 JP 2017532374A5 JP 2017535609 A JP2017535609 A JP 2017535609A JP 2017535609 A JP2017535609 A JP 2017535609A JP 2017532374 A5 JP2017532374 A5 JP 2017532374A5
- Authority
- JP
- Japan
- Prior art keywords
- mannitol
- pharmaceutical composition
- eutectic
- item
- cyclobenzaprine hcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000594 mannitol Substances 0.000 claims description 45
- 229930195725 Mannitol Natural products 0.000 claims description 37
- 235000010355 mannitol Nutrition 0.000 claims description 37
- 229960003572 cyclobenzaprine Drugs 0.000 claims description 36
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 claims description 35
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 230000005496 eutectics Effects 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000005550 wet granulation Methods 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000000155 melt Substances 0.000 claims description 6
- 239000002610 basifying agent Substances 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229940058023 trisodium citrate anhydrous Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 description 5
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000320 mechanical mixture Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462052238P | 2014-09-18 | 2014-09-18 | |
| US62/052,238 | 2014-09-18 | ||
| PCT/US2015/051068 WO2016044796A1 (en) | 2014-09-18 | 2015-09-18 | Eutectic formulations of cyclobenzaprine hydrochloride |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018173466A Division JP6717902B6 (ja) | 2014-09-18 | 2018-09-18 | シクロベンザプリン塩酸塩の共融製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532374A JP2017532374A (ja) | 2017-11-02 |
| JP2017532374A5 true JP2017532374A5 (enExample) | 2018-11-01 |
| JP6614724B2 JP6614724B2 (ja) | 2019-12-04 |
Family
ID=55533932
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017535609A Active JP6614724B2 (ja) | 2014-09-18 | 2015-09-18 | シクロベンザプリン塩酸塩の共融製剤 |
| JP2018173466A Active JP6717902B6 (ja) | 2014-09-18 | 2018-09-18 | シクロベンザプリン塩酸塩の共融製剤 |
| JP2019236602A Withdrawn JP2020059757A (ja) | 2014-09-18 | 2019-12-26 | シクロベンザプリン塩酸塩の共融製剤 |
| JP2021169539A Withdrawn JP2022001605A (ja) | 2014-09-18 | 2021-10-15 | シクロベンザプリン塩酸塩の共融製剤 |
| JP2023116057A Withdrawn JP2023126486A (ja) | 2014-09-18 | 2023-07-14 | シクロベンザプリン塩酸塩の共融製剤 |
| JP2025076812A Pending JP2025107355A (ja) | 2014-09-18 | 2025-05-02 | シクロベンザプリン塩酸塩の共融製剤 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018173466A Active JP6717902B6 (ja) | 2014-09-18 | 2018-09-18 | シクロベンザプリン塩酸塩の共融製剤 |
| JP2019236602A Withdrawn JP2020059757A (ja) | 2014-09-18 | 2019-12-26 | シクロベンザプリン塩酸塩の共融製剤 |
| JP2021169539A Withdrawn JP2022001605A (ja) | 2014-09-18 | 2021-10-15 | シクロベンザプリン塩酸塩の共融製剤 |
| JP2023116057A Withdrawn JP2023126486A (ja) | 2014-09-18 | 2023-07-14 | シクロベンザプリン塩酸塩の共融製剤 |
| JP2025076812A Pending JP2025107355A (ja) | 2014-09-18 | 2025-05-02 | シクロベンザプリン塩酸塩の共融製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10357465B2 (enExample) |
| EP (1) | EP3193854A4 (enExample) |
| JP (6) | JP6614724B2 (enExample) |
| CN (2) | CN112618494B (enExample) |
| AU (2) | AU2015317336B2 (enExample) |
| BR (1) | BR112017005231A2 (enExample) |
| IL (2) | IL251218B (enExample) |
| MX (1) | MX387402B (enExample) |
| MY (1) | MY186047A (enExample) |
| SG (2) | SG11201701995PA (enExample) |
| WO (1) | WO2016044796A1 (enExample) |
| ZA (1) | ZA201701637B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE037281T2 (hu) | 2009-11-20 | 2018-08-28 | Tonix Pharma Holdings Ltd | Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| NZ631152A (en) | 2013-03-15 | 2017-05-26 | Tonix Pharmaceuticals Inc | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| US10357465B2 (en) | 2014-09-18 | 2019-07-23 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride |
| JP2021505629A (ja) | 2017-12-11 | 2021-02-18 | トニックス ファーマ ホールディングス リミテッド | 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置 |
| MX2021002012A (es) * | 2018-08-20 | 2021-04-28 | Tonix Pharma Holdings Ltd | Metodos de tratamiento del trastorno por estres agudo y trastorno por estres postraumatico. |
| NL2023661B1 (en) * | 2019-08-19 | 2021-04-21 | Seranovo Holding B V | Pharmaceutical Eutectic Salt Formulation |
| WO2021207561A1 (en) | 2020-04-08 | 2021-10-14 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for sexual dysfunction |
| EP4247370A1 (en) * | 2020-11-20 | 2023-09-27 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for alcohol use disorder |
| JP2023554692A (ja) * | 2020-12-07 | 2023-12-28 | トニックス ファーマシューティカルズ ホールディング コーポレイション | 線維筋痛症のためのシクロベンザプリン処置 |
| WO2023059728A1 (en) | 2021-10-06 | 2023-04-13 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients |
| CN120379655A (zh) | 2022-06-21 | 2025-07-25 | 通尼克斯医药控股公司 | (sars)-cov-2感染的急性后后遗症(pasc)的环苯扎林治疗 |
| WO2025160302A1 (en) | 2024-01-25 | 2025-07-31 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for acute stress reaction or acute stress disorder |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968507A (en) * | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| SG47101A1 (en) | 1992-07-31 | 1998-03-20 | Us Bioscience | Crystalline amifostine compositions and methods for the preparation and use of same |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| WO1994018954A1 (en) | 1993-02-22 | 1994-09-01 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of biologics and compositions useful therefor |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
| US20030077227A1 (en) | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| WO1999018937A1 (en) * | 1997-10-16 | 1999-04-22 | Merck & Co., Inc. | New cyclobenzaprine composition |
| CA2331542A1 (en) | 1998-05-14 | 1999-11-18 | Alza Corporation | Antidepressant therapy |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| ES2192156B1 (es) | 1999-08-13 | 2005-02-16 | Vela Pharmaceuticals, Inc. | Composiciones de uso para tratar o prevenir alteraciones del sueño usando dosis muy bajas de ciclobenzaprina. |
| US6358944B1 (en) | 1999-08-13 | 2002-03-19 | Vela Pharmaceuticals, Inc. | Methods and compositions for treating generalized anxiety disorder |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| WO2001089476A1 (en) | 2000-05-19 | 2001-11-29 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
| DK1441708T3 (da) | 2001-11-05 | 2009-07-06 | Krele Pharmaceuticals Llc | Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme |
| US7105486B2 (en) | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| US7700561B2 (en) | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US7659253B2 (en) | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| MXPA05004381A (es) | 2002-10-25 | 2006-02-10 | Collegium Pharmaceutical Inc | Estereoisomeros de para-hidroxi-milnacipran y metodos de uso de los mismos. |
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| KR101170840B1 (ko) | 2003-05-29 | 2012-08-03 | 샤이어 엘엘씨 | 남용 방지성 암페타민 화합물 |
| EP1685115A1 (en) | 2003-11-03 | 2006-08-02 | Warner-Lambert Company LLC | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders |
| US20050143350A1 (en) | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
| EP1727520A2 (en) | 2003-12-09 | 2006-12-06 | Medcrystalforms, Llc | Method of preparation of mixed phase co-crystals with active agents |
| KR20070030178A (ko) | 2004-02-17 | 2007-03-15 | 트랜스오랄 파마슈티칼스, 인코포레이티드 | 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법 |
| US8216610B2 (en) | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| US20070196364A1 (en) * | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
| US7532935B2 (en) | 2005-07-29 | 2009-05-12 | Cyberonics, Inc. | Selective neurostimulation for treating mood disorders |
| US7994220B2 (en) | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| US20080146672A1 (en) | 2006-12-08 | 2008-06-19 | Denton Marcia Marye | Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue |
| EP2170064A4 (en) | 2007-06-22 | 2010-08-04 | Merck Sharp & Dohme | 6,5-pyrrolopiperidine tachykinin receptor antagonists |
| NZ583193A (en) | 2007-07-23 | 2012-05-25 | Biotie Therapies Inc | Treatment of post-traumatic stress disorder with nepicastat |
| US20090060983A1 (en) | 2007-08-30 | 2009-03-05 | Bunick Frank J | Method And Composition For Making An Orally Disintegrating Dosage Form |
| US9254268B2 (en) * | 2007-09-25 | 2016-02-09 | Solubest Ltd. | Compositions comprising lipophilic active compounds and method for their preparation |
| EP2203158A4 (en) | 2007-10-30 | 2012-12-26 | Reddys Lab Ltd Dr | PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE |
| US20090148532A1 (en) | 2007-12-06 | 2009-06-11 | Venkatesh Gopi M | Preparation of controlled release skeletal muscle relaxant dosage forms |
| CA3066426A1 (en) | 2008-01-09 | 2009-07-16 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
| US9314469B2 (en) | 2008-05-05 | 2016-04-19 | Tonix Pharma Holdings Limited | Method for treating neurocognitive dysfunction |
| JP5380909B2 (ja) | 2008-05-30 | 2014-01-08 | 株式会社ブリヂストン | 金型及び樹脂発泡成形品の成形方法 |
| US20100266682A1 (en) | 2008-12-10 | 2010-10-21 | Nipun Davar | Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
| EP2233134A1 (en) | 2009-03-27 | 2010-09-29 | McNeil AB | Multi-portion intra-oral dosage form with organoleptic properties |
| US20100247586A1 (en) | 2009-03-27 | 2010-09-30 | Andreas Hugerth | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties |
| US8871263B2 (en) | 2009-09-24 | 2014-10-28 | Mcneil-Ppc, Inc. | Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder |
| HUE037281T2 (hu) | 2009-11-20 | 2018-08-28 | Tonix Pharma Holdings Ltd | Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| WO2012050594A1 (en) | 2010-09-01 | 2012-04-19 | Tonix Pharmaceuticals, Inc. | Treatment for cocaine addiction |
| US11998516B2 (en) * | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| MX382516B (es) * | 2012-06-15 | 2025-03-13 | Tonix Pharmaceuticals Inc | Composiciones y metodos para absorcion transmucosa. |
| NZ631152A (en) * | 2013-03-15 | 2017-05-26 | Tonix Pharmaceuticals Inc | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| US10357465B2 (en) | 2014-09-18 | 2019-07-23 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride |
-
2015
- 2015-09-18 US US15/511,287 patent/US10357465B2/en active Active
- 2015-09-18 CN CN202011576351.9A patent/CN112618494B/zh active Active
- 2015-09-18 EP EP15841528.1A patent/EP3193854A4/en active Pending
- 2015-09-18 MY MYPI2017700889A patent/MY186047A/en unknown
- 2015-09-18 AU AU2015317336A patent/AU2015317336B2/en active Active
- 2015-09-18 MX MX2017003644A patent/MX387402B/es unknown
- 2015-09-18 SG SG11201701995PA patent/SG11201701995PA/en unknown
- 2015-09-18 CN CN201580050140.2A patent/CN107072968B/zh active Active
- 2015-09-18 BR BR112017005231A patent/BR112017005231A2/pt not_active Application Discontinuation
- 2015-09-18 SG SG10201902203VA patent/SG10201902203VA/en unknown
- 2015-09-18 JP JP2017535609A patent/JP6614724B2/ja active Active
- 2015-09-18 WO PCT/US2015/051068 patent/WO2016044796A1/en not_active Ceased
-
2017
- 2017-03-07 ZA ZA2017/01637A patent/ZA201701637B/en unknown
- 2017-03-16 IL IL251218A patent/IL251218B/en active IP Right Grant
-
2018
- 2018-09-18 JP JP2018173466A patent/JP6717902B6/ja active Active
-
2019
- 2019-07-22 US US16/518,338 patent/US11026898B2/en active Active
- 2019-12-26 JP JP2019236602A patent/JP2020059757A/ja not_active Withdrawn
-
2020
- 2020-10-05 IL IL277814A patent/IL277814B/en unknown
- 2020-12-17 AU AU2020289838A patent/AU2020289838B2/en active Active
-
2021
- 2021-10-15 JP JP2021169539A patent/JP2022001605A/ja not_active Withdrawn
-
2023
- 2023-07-14 JP JP2023116057A patent/JP2023126486A/ja not_active Withdrawn
-
2025
- 2025-05-02 JP JP2025076812A patent/JP2025107355A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532374A5 (enExample) | ||
| CN101622302B (zh) | 生产喷雾干燥产品的制剂工艺方法 | |
| RU2597790C2 (ru) | Способ обработки частиц активных фармацевтических ингредиентов | |
| Chang et al. | Anti-hygroscopic effect of leucine on spray-dried herbal extract powders | |
| MA38397A1 (fr) | Agglomérats inhalables de particules de support poreuses et médicament micronisé | |
| JP2018537565A (ja) | 表面反応炭酸カルシウムを含む細粒の製造方法 | |
| JP2016512494A5 (enExample) | ||
| JPWO2019207061A5 (enExample) | ||
| JP2004523594A5 (enExample) | ||
| JP2016515528A5 (enExample) | ||
| JP2009530271A5 (enExample) | ||
| JP2005508977A (ja) | 医薬品化合物中の熱分解法シリカに基づく粒体材料の使用 | |
| RU2016142819A (ru) | Твердая композиция, содержащая аморфный софосбувир | |
| RU2018144108A (ru) | Никотиносодержащие частицы | |
| CN102861106A (zh) | 一种复方氨酚烷胺微丸的制备方法 | |
| RU2018112077A (ru) | Направленная доставка высушенных распылением композиций в легкие | |
| HRP20161624T1 (hr) | Produkt ko-mikronizacije koji sadrži ulipristal acetat | |
| CN103948933A (zh) | 一种白藜芦醇包合物及其制剂的制备方法 | |
| JP2012509922A5 (enExample) | ||
| JP2024513468A (ja) | ニコチン含有凝集体およびその形成方法 | |
| CN103891786A (zh) | 一种驱蚊喷雾剂及其制备方法 | |
| CN103655495B (zh) | 一种辅料种类和用量少的硫辛酸片剂及其制备方法 | |
| CN102145017B (zh) | 改善中药提取液喷雾干燥过程中热熔型粘壁的方法 | |
| CN101954104A (zh) | 一种丹皮酚固体分散体空气清新剂 | |
| CN204446657U (zh) | 一种蒙药丸剂剂型结构 |